Scientific Advisory Board
Prima BioMed’s Scientific Advisory Board (SAB) is led by distinguished Australian Scientist Professor Ian Frazer. The SAB provide independent review of Prima BioMed's product development programs and new product opportunities.
Ian Frazer, AC, FRS, FAA
Professor Ian Frazer, AC, is Chief Executive Officer (CEO) and Director of Research of Translational Research Institute in Brisbane, Australia. In this role, he heads an expert cohort of over 650 researchers from four leading medical research institutes. The University of Queensland Diamantina Institute (UQDI), Queensland University of Technology Institute for Biomedical and Health Innovation (IHBI), Mater Research and Princess Alexandra Hospital Centres for Health Research (MRPAHCHR) and DSM Biologics.
Internationally renowned for the co-creation of the technology for the cervical cancer vaccines, Professor Frazer began his career as a renal physician and clinical immunologist in Edinburgh, Scotland, before immigrating in 1981 to Melbourne, Australia. He continued his clinical training and pursued studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay. In 1985, he was appointed Director of The University of Queensland Diamantina Institute in 1991 until he became CEO of the TRI. He retains an active research program at the Institute in immune responses to cancer and cancer immunotherapy.
Professor Frazer was awarded the 2005 CSIRO Eureka Prize for Leadership in Science and was selected as Queenslander of the Year, and Australian of the Year in 2006. He was also awarded the 2008 Prime Minister‘s Prize for Science, the 2008 Balzan Prize for Preventive Medicine, the 2009 Honda Prize, and, in 2011, was elected as a Fellow of the esteemed Royal Society of London. In 2012, Professor Frazer was appointed a Companion of the Order of Australia (AC) in the Queen’s Birthday Honours.
Bruce Loveland, PhD
Associate Professor Bruce Loveland is a cellular immunologist with expertise in immunogenetics, T lymphocyte functions, dendritic cells, cancer, and transplantation immunology. His current positions at the Burnet Institute, Melbourne, Australia, are Head, Research Support and Facilities, co-head of the HCV Immunotherapy Laboratory, and Quality Manager for the Burnet ImmunoMonitoring Facility (NATA R&D accredited). His Ph.D. studies defined T cells that induce skin allograft rejection in mice (Melbourne University, 1981) which led to research in London (MRC Clinical Research Centre, Harrow, 1981-1986) and Dallas (Howard Hughes Medical Institute, 1986-1989) investigating minor transplantation antigens.
He continued his immunological research from 1990 at the Austin Research Institute and upon merger with the Burnet Institute in 2006 worked on immunotherapy research and translation into clinical trials involved in protocol design and clinical trial management, including negotiations with commercial manufacturers for GMP materials and cell processing, technical transfers from the research laboratory to commercial subcontractors, and reporting to regulatory agencies, funding bodies, research institutions, and biopharma companies.
From 2008-2011, he was the Burnet project manager for the construction, outfitting, and occupancy of the Alfred Centre (Stage 2) building project; in particular, the 3,700 square meters laboratory floor which currently accommodates 100 scientists, and he continues to provide research management at the Burnet Institute for their approximately 300 Melbourne-based staff and PC2 and PC3 laboratory facilities.
Michael Szardenings, PhD
Michael is head of the Ligand Development Group at Fraunhofer IZI in Leipzig Germany. His personal research interests are proteins, their structures and interactions. Applying, amongst others, peptide phage display technology, his ongoing research is primarily focused on immune responses in the context of allergies and infections.
Michael joined Fraunhofer in 2009 after more than ten years as CSO or CBO in biotech and CRO/CMO companies. He holds a diploma in chemistry from the University Hamburg (1986) and a Ph.D. in protein design (1989) from Germany’s National Biotechnology Research Center (GBF).
After a postdoctoral in protein crystallography, he was active as researcher and lecturer in receptor pharmacology at the University of Uppsala (Sweden) before starting as CSO with a phage display company in 1998.
Holden T. Maecker, PhD
Dr Maecker is an Associate Professor of Microbiology and Immunology, and Director of the Human Immune Monitoring Center at Stanford University. His research focuses on cellular immune responses to chronic pathogens and cancer, and the correlation of those responses with immune protection. Dr Maecker received his Ph.D. from Stanford University, where he also did postdoctoral work. He previously held positions at Loyola University, Chicago, and BD Biosciences, San Jose, California.
Chris Schmidt, PhD
Dr. Schmidt received his Ph.D. in the immunology of Epstein-Barr virus in 1996, through the University of Queensland. He then assumed responsibility for product development, manufacture, clinical trial development, and immunological analysis for a series of novel immunotherapeutics, mostly based on patient-derived dendritic cells and tumor cells. Over the next 15 years, he was the chief investigator on in eight human clinical immunotherapy trials for melanoma, prostate cancer, glioblastoma, and hepatocellular carcinoma, including the world’s first Phase III trial for dendritic cell therapy of resected metastatic melanoma. He was head of the Cancer Immunotherapy Laboratory at the Queensland Institute of Medical Research from 2002-2012.
Dr. Schmidt is the recipient of the ASMR Queensland Premiers Award, the Cancer Council Queensland “Beccy Bourn Melanoma Research Grant” Award, and was the Gordon Ada Orator for the Australasian Society for Immunology in 2010.
The main focus of his research is modeling how T cells effect objective clinical responses against metastatic cancers. This approach considers multiple factors, including intrinsic qualities of the cancer and the immunotherapeutic, and the anti-cancer immune response. The critical advantage that drives this work is access to tumor cell lines derived from the clinical trial patients, allowing antigen discovery and genetic analysis through collaboration with several of the worlds’ leading cancer immunology and genetics groups.
Dr. Schmidt is currently a chief investigator on a project developing personalized cancer vaccines in the Oncogenomics Laboratory at QIMR.
Clinical Advisory Board
The Prima BioMed Clinical Advisory Board (CAB) is a group of key opinion leaders and therapeutic specialists who advise the Company on new clinical opportunities to acquire or co-develop products that complement its mission.
Prima BioMed is currently forming a new Clinical Advisory Board for its AIPAC-trial.